NCT04558242 is a NA clinical trial of Genix in Androgenetic Alopecia, sponsored by Kiierr International, LLC.

Who is sponsoring NCT04558242?

NCT04558242 is sponsored by Kiierr International, LLC.

What drugs are being tested in NCT04558242?

Interventions in NCT04558242: Genix, Sham.

What condition does NCT04558242 study?

NCT04558242 studies Androgenetic Alopecia, Hair Loss, Thinning Hair, Balding.

Is NCT04558242 still recruiting?

NCT04558242 is currently status unknown. Last updated 22 September 2020.

Last reviewed 2020-09-22 · How we verify

NCT04558242

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low Level Light Device as a Primary Therapy for Androgenetic Alopecia

Status unknown NA Last updated 22 September 2020

What this trial tests

NA trial testing Genix in Androgenetic Alopecia in 50 participants. Status unknown.

Timeline

1 August 2020

Primary endpoint
1 May 2021

1 August 2021

Quick facts

Lead sponsor	Kiierr International, LLC
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	1 August 2020
Primary completion	1 May 2021
Estimated completion	1 August 2021
Sites	1 location across United States

Drugs / interventions tested

Genix
Sham

Conditions studied

Androgenetic Alopecia — all drugs for Androgenetic Alopecia →
Hair Loss — all drugs for Hair Loss →
Thinning Hair — all drugs for Thinning Hair →
Balding — all drugs for Balding →

Sponsor

Kiierr International, LLC

Who can join

Adults 18 to 70, any sex, with Androgenetic Alopecia or Hair Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to study the safety and effectiveness of a light therapy device for human hair growth. This device, called the GENIX, is a type of cold, or non-heat producing light emitting diode (LED) that will emit light on the hair growth cells within and around the hair follicle. When these cells do not function properly, one may experience common problems such as baldness and thinning or brittle hair. The application of a special category of low-level non-laser light to be studied in the project may cause an increase in essential nutrients to the damaged hair follicles and skin cells, leading to a reduction in hair loss and in some cases, possibly leading to re-growth.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Androgenetic Alopecia

Currently open trials in the same condition.

NCT07429253 — Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients · Phase 1, PHASE2 · recruiting
NCT06841458 — Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04558242 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kiierr International, LLC
Last refreshed: 22 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04558242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing